One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Autoinjectors Market

自動注射器市場ー業界洞察、主要プレーヤー・企業別、成長機会別、最新傾向別、開発別、主要な成長ドライバー別、主要な課題別によってセグメンテーション、予測 2023年


[ 英語タイトル ] Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023


Product Code : MNMHC00110081
Survey : MarketsandMarkets
Publish On : March, 2021
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD5650 / Question Form
5 User USD6650 / Question Form
Enterprise User USD10000 / Question Form

[Report Description]

“The autoinjectors market is projected to grow at a CAGR of 24.2% during the forecast period.”
The global autoinjectors market is expected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period. Growing prevalence of targeted therapies, rising incidence of anaphylaxis, increasing number of regulatory approvals, and technological advancements in autoinjector devices are expected to drive the growth of the autoinjectors market. However, the preference for alternative routes of drug delivery such as oral diabetic agents and epinephrine nasal sprays is expected to restrain the growth of this market to a certain extent.

“By therapy, the rheumatoid arthritis segment is expected to grow at the highest CAGR during the study period.”
Based on therapy, the global autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies. The rheumatoid arthritis segment is expected to grow at the highest CAGR during the forecast period. The high growth of the segment can be primarily attributed to the high prevalence of rheumatoid arthritis across the globe.

“By type, the disposable autoinjectors segment is expected to grow at the highest rate during the forecast period (2018–2023).”
Based on type, the market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the benefits these autoinjectors offer, such as portability, ease of use, and a lower possibility of infection.

“The North American autoinjectors market is expected to grow at the highest CAGR during the forecast period.”
North America is expected to witness the highest growth from 2018 to 2023. This can be attributed to the rising prevalence of anaphylaxis, autoimmune diseases, and chronic diseases in the US and Canada; favorable reimbursement scenario; and increasing number of awareness programs in the region.

Break of primary participants was as mentioned below:

The key players in the global autoinjectors market are Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US), Merck (US), Ypsomed (Switzerland), AstraZeneca (UK), J&J (US), Becton Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), Bayer (Germany), and Haselmeier (Switzerland).
Research Coverage:
The report analyzes the autoinjectors market and aims at estimating the market size and future growth potential of this market based on various segments such as therapy, type, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater share. Firms purchasing the report could use one or any combination of the below mentioned five strategies.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the autoinjectors market. The report analyzes the market based on therapy, type, end user, and region
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the autoinjectors market
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various autoinjectors across regions
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the autoinjectors market
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the market

TABLE OF CONTENTS

1 INTRODUCTION 14
1.1 OBJECTIVES OF STUDY 14
1.2 MARKET DEFINITION 14
1.3 MARKET SCOPE 15
1.3.1 YEARS CONSIDERED FOR THE STUDY 15
1.3.2 MARKETS COVERED 15
1.4 CURRENCY 16
1.5 LIMITATIONS 16
1.6 STAKEHOLDERS 16
2 RESEARCH METHODOLOGY 17
2.1 RESEARCH METHODOLOGY STEPS 17
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 18
2.2.1 SECONDARY RESEARCH 18
2.2.2 PRIMARY RESEARCH 20
2.2.2.1 key data from primary sources 21
2.2.2.2 Key industry insights 22
2.3 MARKET SIZE ESTIMATION METHODOLOGY 22
2.4 MARKET DATA VALIDATION AND TRIANGULATION 25
2.5 ASSUMPTIONS FOR THE STUDY 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 31
4.1 AUTOINJECTORS MARKET OVERVIEW 31
4.2 AUTOINJECTORS MARKET, BY TYPE, 2018 VS. 2023 32
4.3 GEOGRAPHIC ANALYSIS: AUTOINJECTORS MARKET, BY THERAPY 33
4.4 AUTOINJECTORS MARKET, BY END USER, 2018 VS. 2023 34
4.5 GEOGRAPHIC SNAPSHOT: AUTOINJECTORS MARKET 34
5 MARKET OVERVIEW 35
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 DRIVERS 36
5.2.1.1 Growing prevalence of targeted therapies 36
5.2.1.2 Rising incidence of anaphylaxis 37
5.2.1.3 Increasing number of regulatory approvals 37
5.2.1.4 Availability of generic versions of autoinjectors 38
5.2.1.5 Favorable reimbursements and government support 38
5.2.1.6 Technological advancements and design development 38
5.2.2 RESTRAINTS 39
5.2.2.1 Preference for alternative drug delivery modes 39
5.2.2.1.1 Oral diabetic agents and oral insulin 39
5.2.2.1.2 Epinephrine nasal sprays 39
5.2.3 OPPORTUNITIES 40
5.2.3.1 Patent expiry of biologics to drive the demand for biosimilars 40
5.2.4 CHALLENGES 41
5.2.4.1 Development of autoinjectors for multiple drug viscosities 41
5.2.4.2 Lack of proper training for using autoinjectors 41
6 AUTOINJECTORS MARKET, BY THERAPY 42
6.1 INTRODUCTION 43
6.2 RHEUMATOID ARTHRITIS 44
6.3 MULTIPLE SCLEROSIS 45
6.4 DIABETES 46
6.5 ANAPHYLAXIS 47
6.6 OTHER THERAPIES 48
7 AUTOINJECTORS MARKET, BY TYPE 50
7.1 INTRODUCTION 51
7.1.1 DISPOSABLE AUTOINJECTORS 53
7.1.2 REUSABLE AUTOINJECTORS 54
8 AUTOINJECTORS MARKET, BY END USER 55
8.1 INTRODUCTION 56
8.2 HOME CARE SETTINGS 57
8.3 HOSPITALS & CLINICS 58
9 AUTOINJECTORS MARKET, BY REGION 60
9.1 INTRODUCTION 61
9.2 NORTH AMERICA 63
9.2.1 US 65
9.2.2 CANADA 69
9.3 EUROPE 71
9.3.1 GERMANY 74
9.3.2 UK 75
9.3.3 FRANCE 77
9.3.4 REST OF EUROPE 79

9.4 ASIA PACIFIC 81
9.4.1 JAPAN 84
9.4.2 CHINA 85
9.4.3 INDIA 87
9.4.4 ROAPAC 88
9.5 REST OF THE WORLD 91
10 COMPETITIVE LANDSCAPE 94
10.1 OVERVIEW 94
10.2 MARKET SHARE ANALYSIS 94
10.3 MARKET RANKING OF OEM COMPANIES 94
10.4 MARKET SHARE ANALYSIS, BY THERAPEUTIC AREA 95
10.4.1 RHEUMATOID ARTHRITIS 95
10.4.2 MULTIPLE SCLEROSIS 96
10.4.3 DIABETES 96
10.4.4 ANAPHYLAXIS 97
10.5 COMPETITIVE SCENARIO 98
10.5.1 PRODUCT LAUNCHES AND APPROVALS 99
10.5.2 EXPANSIONS 100
10.5.3 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 100
11 COMPANY PROFILES 101
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1 ABBVIE 101
11.2 MYLAN 104
11.3 ELI LILLY 106
11.4 YPSOMED 108
11.5 AMGEN 110
11.6 BECTON, DICKINSON AND COMPANY 112
11.7 OWEN MUMFORD 114
11.8 CONSORT MEDICAL 115
11.9 HASELMEIER 117
11.10 SHL GROUP (SCANDINAVIAN HEALTH LIMITED) 118
11.11 JOHNSON & JOHNSON (J&J) 119
11.12 TEVA 121
11.13 ANTARES PHARMA 123
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12 APPENDIX 125
12.1 DISCUSSION GUIDE 125
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 129
12.3 AVAILABLE CUSTOMIZATIONS 131
12.4 RELATED REPORTS 132
12.5 AUTHOR DETAILS 133

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+